BioSpace News Archive

Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced the 60 day results from the randomized controlled trial of remestemcel-L in 222 ventilator-dependent COVID-19 patients with moderate/severe acute respiratory distress syndrome (ARDS) which had been halted after the third interim analysis, as previously announced.

Mesoblast Limited, global leader in allogeneic cellular medicines for inflammatory diseases, will host a webcast to provide a corporate update.

April 29, 2021 – Second lot recalled due to presence of nitrosamine impurity Apotex Inc. is recalling a second lot of APO-Amitriptyline 10 mg tablets, after testing identified NDMA, a nitrosamine impurity, above the acceptable limit.

Werewolf Therapeutics, Inc. (NASDAQ: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer, today announced the pricing of its upsized initial public offering of 7,500,000 shares of common stock at a public offering price of $16.00 per share

AVITA Medical, Inc., a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, announced it plans to release its fiscal third quarter 2021 financial results after the market closes on Thursday, May 13, 2021.

Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, announced that it will report first quarter 2021 financial results after the U.S. financial markets close on Thursday, May 6, 2021.

Sonic Urges Company to Add Its Three Independent Nominees to Board to Bring the Exact Experience and Perspectives Adverum Desperately Needs

10x Genomics, Inc., announced the company will be participating in the upcoming BofA Securities 2021 Virtual Healthcare Conference.

Lucira Health, Inc., a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits, announced that the company will report first quarter ended March 31, 2021 financial results on Thursday, May 13, 2021.

Idera Pharmaceuticals, Inc. (“Idera” or the “Company”) (Nasdaq: IDRA) today reported its financial and operational results for the first quarter ended March 31, 2021.